Home   >  
Cell Cycle/DNA Damage

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials


Chemical Structure Cat. No. Product Name CAS No.
Elafibranor Chemical Structure
BCP31152 Elafibranor 824932-88-9
Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
Bocidelpar Chemical Structure
BCP45760 Bocidelpar 2095128-20-2
Bocidelpar is a peroxisome proliferator-activated receptor (PPAR) delta agonist.
SR1664 Chemical Structure
BCP45759 SR1664 1338259-05-4
SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity.
AMG-131 Chemical Structure
BCP45654 AMG-131 315224-26-1
AMG-131 is a hypoglycemic agent. It is a potent PPARγ partial agonist that displays robust glucose-lowering activity in rodent models of diabetes while exhibiting a reduced side-effects profile compared to marketed TZDs.
NXT629 Chemical Structure
BCP44937 NXT629 1454925-59-7
NXT629 is a potent, selective, and competitive PPAR-α antagonist.
EHP-101 Chemical Structure
BCP43165 EHP-101 1818428-24-8
EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases.
Fmoc-L-Leucine Chemical Structure
BCP39156 Fmoc-L-Leucine 35661-60-0
NPC 15199 is an amino acid derivative.
Lobeglitazone Chemical Structure
BCP37672 Lobeglitazone 607723-33-1
Lobeglitazone is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Besides its activation of peroxisome proliferator-activated receptor (PPAR) gamma, lobeglitazone is also a potent agonist for PPARalpha.
GW6471 Chemical Structure
BCP35208 GW6471 880635-03-0
GW 6471 is a potent PPARα antagonist.
LY518674 Chemical Structure
BCP34904 LY518674 425671-29-0
LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis.
123下一页末页共 55 条记录 1 / 6 页